Literature DB >> 30023092

Malignant pleural mesothelioma: main topics of American Society of Clinical Oncology clinical practice guidelines for diagnosis and treatment.

Malgorzata Szolkowska1, Katarzyna Blasinska-Przerwa2, Magdalena Knetki-Wroblewska3, Piotr Rudzinski4, Renata Langfort1.   

Abstract

Entities:  

Year:  2018        PMID： 30023092      PMCID： PMC6036026          DOI： 10.21037/jtd.2018.04.106

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.

Authors:  R T Heelan; V W Rusch; C B Begg; D M Panicek; J F Caravelli; C Eisen
Journal:  AJR Am J Roentgenol       Date:  1999-04       Impact factor: 3.959

2.  A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.

Authors:  Anne S Tsao; Linda Garland; Mary Redman; Kemp Kernstine; David Gandara; Edith M Marom
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

Review 3.  Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations.

Authors:  Mylene T Truong; Chitra Viswanathan; Myrna B C Godoy; Brett W Carter; Edith M Marom
Journal:  Semin Roentgenol       Date:  2013-10       Impact factor: 0.800

4.  B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.

Authors:  Aaron Scott Mansfield; Anja C Roden; Tobias Peikert; Yuri M Sheinin; Susan M Harrington; Christopher J Krco; Haidong Dong; Eugene D Kwon
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

5.  Chest physician-reported, work-related, long-latency respiratory disease in Great Britain.

Authors:  Melanie Carder; Andrew Darnton; Matthew Gittins; S Jill Stocks; David Ross; Chris M Barber; Raymond M Agius
Journal:  Eur Respir J       Date:  2017-12-28       Impact factor: 16.671

6.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Authors:  Aliya Noor Husain; Thomas V Colby; Nelson G Ordóñez; Timothy Craig Allen; Richard Luther Attanoos; Mary Beth Beasley; Kelly Jo Butnor; Lucian R Chirieac; Andrew M Churg; Sanja Dacic; Françoise Galateau-Sallé; Allen Gibbs; Allen M Gown; Thomas Krausz; Leslie Anne Litzky; Alberto Marchevsky; Andrew G Nicholson; Victor Louis Roggli; Anupama K Sharma; William D Travis; Ann E Walts; Mark R Wick
Journal:  Arch Pathol Lab Med       Date:  2017-07-07       Impact factor: 5.534

7.  Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.

Authors:  Raja M Flores; Timothy Akhurst; Mithat Gonen; Steven M Larson; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2003-07       Impact factor: 5.209

8.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

Review 9.  Diagnostic Imaging and workup of Malignant Pleural Mesothelioma.

Authors:  Luciano Cardinale; Francesco Ardissone; Dario Gned; Nicola Sverzellati; Edoardo Piacibello; Andrea Veltri
Journal:  Acta Biomed       Date:  2017-08-23

10.  Turkey National Mesothelioma Surveillance and Environmental Asbestos Exposure Control Program.

Authors:  Selma Metintaş; Hasan Fevzi Batırel; Hasan Bayram; Ülkü Yılmaz; Mehmet Karadağ; Güntülü Ak; Muzaffer Metintaş
Journal:  Int J Environ Res Public Health       Date:  2017-10-25       Impact factor: 3.390
View more
  3 in total

1.  Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.

Authors:  Jeronimo Rafael Rodríguez-Cid; Orlando García-Acevedo; Javier Benjamin-Contreras; Diana Bonilla-Molina; Rodrigo Rafael Flores-Mariñelarena; Luis Martínez-Barrera; Jorge Arturo Alatorre-Alexander; Carla Paola Sanchez-Ríos; Maria Del Rosario Flores-Soto; Patricio Javier Santillan-Doherty; Erika Sagrario Peña-Mirabal
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

2.  A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma.

Authors:  Irene Dell'Anno; Alessandra Melani; Sarah A Martin; Marcella Barbarino; Roberto Silvestri; Monica Cipollini; Antonio Giordano; Luciano Mutti; Andrea Nicolini; Luca Luzzi; Raffaele Aiello; Federica Gemignani; Stefano Landi
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

Review 3.  Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

Authors:  Thomas G Johnson; Karin Schelch; Sunali Mehta; Andrew Burgess; Glen Reid
Journal:  Front Cell Dev Biol       Date:  2019-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.